Enhanced Quinone-Containing Conjugates for Improved Efficacy and Reduced Toxicity

The present disclosure relates to improved quinone-containing conjugates for detection and treatment of proliferative disorders, featuring enhanced stability, reduced toxicity, and improved tumor cell selectivity.

The original patent disclosed quinone-containing conjugates with limitations in stability, toxicity, and tumor cell selectivity. The new inventive concept addresses these limitations by introducing optimized linker modules, cytotoxic payload modules, and improved conjugate synthesis methods.

The new conjugates comprise a quinone-containing linker module designed for improved stability and reduced toxicity, and a cytotoxic payload module optimized for enhanced efficacy. The conjugates can be synthesized using a system comprising the quinone-containing linker module and the cytotoxic payload module. The inventive concept also includes methods for detecting and treating proliferative disorders using the improved conjugates, which can be administered at lower doses due to their enhanced efficacy and reduced side effects.

The new claims introduce novel and non-obvious features, including the optimized quinone-containing linker module, the improved conjugate synthesis system, and the methods for detecting and treating proliferative disorders using the enhanced conjugates.

Alternative embodiments of the inventive concept may include variations of the quinone-containing linker module, such as different quinone structures or linker lengths. Additionally, the conjugate synthesis system could be modified to include additional components or steps to further improve conjugate stability and efficacy.

The enhanced quinone-containing conjugates have significant commercial potential in the pharmaceutical industry for the detection and treatment of proliferative disorders, offering improved efficacy and reduced toxicity compared to existing treatments.